PRESENTATION

Q4 2024 — Presentation

Q4 2024PDF · 18 pages236 KB
Elevance Health
4Q 2024 Earnings Presentation
January 23, 2025

-- 1 of 18 --

22
The Value We Deliver
We advance whole health through innovative solutions that integrate physical,
behavioral, and social care to achieve our purpose of improving the health of humanity
For Consumers
Simple, Affordable, and Accessible Health Care
1. 	Simplifying healthcare through enhanced digital
capabilities that personalize member experiences
2. 	Affordability at the core of our innovative plan designs
3. 	Accessibility through advocacy and data driven solutions
that operationalize whole health
1. 	Differentiated clinical partnerships built on shared
expertise and coordinated care
2. 	Advanced clinical collaboration and value-based care
3. 	Aligned business partner through digital tools
that enhance information exchange and reduce
administrative burden
For Care Providers
Deepen Clinical and Business Partnerships

-- 2 of 18 --

3
Key Highlights
• 	Elevance Health fourth quarter results were consistent with guidance
• 	4Q 2024 and full year operating revenue of $45.0 and $175.2 billion, respectively
• 	4Q 2024 and full year medical loss ratio of 92.4% and 88.5%, respectively
• 	4Q 2024 and full year adjusted diluted EPS1 of $3.84 and $33.04, respectively
2024 Results
1
• 	2025 adjusted diluted EPS1 in the range of $34.15 – $34.85
• 	Operating revenue expansion in the high single to low double digit percentage range reflects revenue
acceleration across most major lines of business and the impact of recent acquisitions
• 	Medical loss ratio projected to be 89.1% +/- 50 bps
• 	Adjusted Operating gain1 projected to be in the range of $9.55 - $9.85 billion
• 	Medical membership expected to end in the range of 45.8 – 46.6 million members
2025 Outlook
2
• 	Partnering with states to ensure rates accurately reflect higher Medicaid cost trends, building upon our
positioning and performance in 2025 Medicare Advantage annual enrollment, and delivering innovative,
affordable products in the Commercial market
• 	Expanding Carelon capabilities to further drive our enterprise flywheel for growth
• 	Investing to position Elevance Health for long-term, sustainable growth as we ensure the earnings power of
our diverse and complementary businesses remains strong
Strategic Focus Areas
3
1. 	See “GAAP Reconciliation” on slides 15 and 16 herein.

-- 3 of 18 --

44
Key Highlights
• 	Elevance Health fourth quarter and
full year results were consistent with
guidance
• 	Operating revenue of $175.2B in 2024
grew approximately 3% on improved
premium yields in Health Benefits,
acquisitions completed in 2024, and
growth in CarelonRx product revenue,
partly offset by Medicaid membership
attrition
• 	Medical loss ratio of 88.5% for the year,
an increase of 150 bps, primarily
reflects higher Medicaid cost trends
• 	Adjusted operating expense ratio in
2024 of 10.6%, an improvement of 70
bps, reflects disciplined cost
management and certain non-
recurring expense benefits
• 	Operating cash flow of $5.8B, or 1.0
times net income
Fourth Quarter & Full Year 2024 Results
Change
(%/bps/$)
2023	2024
Change
(%/bps)
4Q 2023	4Q 2024	Elevance Health
2.9%	$170.2B	$175.2B	6.0%	$42.5B	$45.0B	Operating Revenue 1
150 bps	87.0%	88.5%	320 bps	89.2%	92.4%	Medical Loss Ratio
(70) bps	11.3%	10.6%	(170) bps	11.6%	9.9%
Adjusted Operating
Expense Ratio1,2
(1.1%)	$9.4B	$9.3B	(24.0%)	$1.4B	$1.0B
Adjusted Operating
Gain1,2
(20) bps	5.5%	5.3%	(90) bps	3.2%	2.3%
Adjusted Operating
Margin 1,2
12.4%	$1.8B	$2.1B	(0.4%)	$529M	$527M	Net Investment Income
(0.3%)	$33.14	$33.04	(31.7%)	$5.62	$3.84	Adjusted Diluted EPS 2
($2.3B)	$8.1B	$5.8B	$3.7B	($3.0B)	$0.7B	Operating Cash Flow
1. 	See “Basis of Presentation” on slide 14 herein.
2. 	See “GAAP Reconciliation” on slides 15 and 16 herein.

-- 4 of 18 --

55
2024 Actual	2025 Outlook	Elevance Health
$144.2B	Low Double Digit Growth	Premium Revenue
$22.6B	Low Single Digit Growth	Product Revenue
$8.4B	Approximately Flat	Service Fees
$175.2B
High Single to Low Double
Digit Growth
Total Operating Revenue1
88.5%	89.1% +/- 50 bps	Medical Loss Ratio
10.6%	10.4% +/- 50 bps	Adjusted Operating Expense Ratio 1,2
$9.3B	$9.55 – $9.85B	Adjusted Operating Gain 1,2
$2.05B	~$1.88B	Net Investment Income
$1.19B	~$1.48B	Interest Expense
$33.04	$34.15 – $34.85	Adjusted Diluted EPS 2
$5.8B	Approximately $8.0B	Operating Cash Flow
2025 Outlook
Key Highlights
• 	2025 full year guidance for adjusted
diluted earnings per share in the
range of $34.15 – $34.85
• 	Operating revenue outlook reflects
the impact of higher premium yields
and recent acquisitions
• 	Medical loss ratio expected to be up
60 bps at the midpoint; medical cost
trend expected to be elevated but
stable; mix headwind from recent
acquisitions
• 	Adjusted operating expense ratio to
be 20 bps below 2024 levels at the
midpoint due to ongoing operating
efficiencies and targeted expense
actions
• 	Net investment income declines on
lower cash balances and rate
outlook; interest expense increases
following recent acquisitions
1. 	See “Basis of Presentation” on slide 14 herein.
2. 	See “GAAP Reconciliation” on slides 15 and 16 herein.

-- 5 of 18 --

66
Key Highlights
• 	Health Benefits results reflect
navigation of a dynamic operating
environment due to Medicaid cost
pressure, partly offset by strong
performance in Commercial
• 	Operating revenue grew 2.8% year
over year in the fourth quarter driven
by higher premium yields, offset by
declines in Medicaid membership
• 	Adjusted operating margin was
impacted by higher cost trend in
Medicaid related to redeterminations
• 	Guidance for operating revenue
growth reflects slight membership
gains and rate improvement
• 	Operating margin expectations
reflect mix impacts, a prudent view of
Medicaid cost trend, and lapping
non-recurring expense benefits
Change
(%/bps)
2023	2024
Change
(%/bps)
4Q 2023	4Q 2024	Health Benefits
1.1%	$148.6B	$150.3B	2.8%	$36.5B	$37.6B	Operating Revenue 1
(8.4%)	$6.9B	$6.3B	(64.4%)	$767M	$273M	Adjusted Operating Gain1,2
(40) bps	4.6%	4.2%	(140) bps	2.1%	0.7%	Adjusted Operating Margin 1,2
(2.3%)	46.8M	45.7M	Membership 3
1. 	See “Basis of Presentation” on slide 14 herein.
2. 	See “Reportable Segment Highlight Details” on slide 17 herein.
3. 	Health Benefits Membership for the three months ended December 31, 2023, is restated to reflect a change in BlueCard® membership to align to the Blue Cross Blue Shield
Association reporting methodology. For the three months ended December 31, 2023, BlueCard® membership has been restated lower by 132K.
2025 Outlook	Guidance
High Single Digit	Operating Revenue Growth
(50) – (25) basis points over 2024	GAAP Operating Margin
45.8M – 46.6M	Membership
Health Benefits
2024 Results | 2025 Outlook

-- 6 of 18 --

77
Key Highlights
• 	Substantial progress in scaling our
enterprise flywheel for growth; in the
fourth quarter, we closed on the
acquisitions of Kroger Specialty
Pharmacy and CareBridge, further
broadening the solutions offered to
clients
• 	CarelonRx fourth quarter operating
revenue includes the impact of recent
acquisitions and strong external
member growth; 2025 operating
margin remains within our target
range of 6.0% – 6.5%
• 	Carelon Services operating revenue
expansion in 4Q 2024 driven by the
launch and growth of risk-based
products and recent acquisitions;
2025 operating margin includes
dilutive impacts of the CareBridge
acquisition and scaling our risk-
based capabilities
2024 Results | 2025 Outlook
Change
(%/bps)
2023	2024
Change
(%/bps)
4Q 2023	4Q 2024	Carelon
12.4%	$48.0B	$53.9B	18.9%	$12.4B	$14.7B	Operating Revenue 1
16.9%	$2.7B	$3.1B	32.3%	$592M	$783M	Adjusted Operating Gain1,2
30 bps	5.5%	5.8%	50 bps	4.8%	5.3%	Adjusted Operating Margin 1,2
3.2%	308.4M	318.4M	6.3%	78.0M	82.9M	Adjusted Scripts
(2.1%)	103.3M	101.1M	Consumers Served
1. 	See “Basis of Presentation” on slide 14 herein.
2. 	See “Reportable Segment Highlight Details” on slide 17 herein.
2025 Outlook	Guidance
Greater than 50%	Carelon Services Operating Revenue Growth
(100) – (50) basis points over 2024	Carelon Services GAAP Operating Margin
Mid Teens	CarelonRx Operating Revenue Growth
0 – 20 basis points over 2024	CarelonRx GAAP Operating Margin
Health Services

-- 7 of 18 --

88
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Approximately 46M medical members
balanced across commercial,
Medicaid and Medicare, leveraging
the assets and capabilities of Carelon
to accelerate growth
Integrated portfolio of whole health
solutions connecting care across
physical, behavioral, social, home
health, and pharmacy needs to bend
the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 8 of 18 --

99
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1
Long-Term Growth Algorithm
Revenue Growth
High Single Digit CAGR1
Adjusted Operating Margin
Expanding to 6.5% - 7.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by membership growth, cost trend, geographic
expansion, and growth in specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk-based revenue growth including M&A
CarelonRx
Low Double Digit CAGR
Driven by script volumes and drug mix
Transforming our business
processes by leveraging new
technologies across operations
Commitment to operating
efficiency and optimizing core
businesses
Effective medical management
Underwriting discipline
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
Targeting at least 12% average annual growth in Adjusted Diluted EPS
1. 	CAGR = Compound Annual Growth Rate Target.

-- 9 of 18 --

10	10
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2024 	Target
$175B
High Single
Digit CAGR1
2024 	Target
Elevance Health
5.8%
Mid to High
Single Digit
2024 	Target
$54B
Mid Teens
CAGR1
2024 	Target
Carelon 2
4.2%
5.5% – 6.5%
2024 	Target
$150B
Mid to High
Single Digit
CAGR1
2024 	Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted 3
Operating
Margin
Revenue
(in billions)
1. 	CAGR = Compound Annual Growth Rate Target.
2. 	The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx,
and (ii) a high teens to low twenties revenue CAGR and mid to high single digit operating margin for Carelon Services.
3. 	See “GAAP Reconciliation” on slides 15 and 16 herein.

-- 10 of 18 --

11	11
The Value We Deliver for Consumers
Simple, Affordable, and Accessible Health Care
• 	More than a third of member interactions are facilitated through ‘live-chat’ functions, ensuring
real time solutions to customer needs
• 	Investing in our Sydney Health app to personalize the health experience and proactively
answer member inquiries
Simplifying healthcare through
enhanced digital capabilities that
personalize member experiences1
• 	Over 90% of our MA plans have no monthly premium in 2025; nearly all plans offer $0 copays
for primary care visits and at least one supplemental benefit
• 	Use of MA supplemental benefits was associated with a decreased likelihood of an inpatient
admission and increased likelihood of an annual wellness visit or preventative screening
• 	Care Transition Interventions (CTI) program led to a 14% decrease in costs for participants
• 	Complex Care Management for Medicaid members reduced inpatient admissions by 7%
Affordability at the core of
our innovative plan designs	2
• 	Targeted digital interventions in 2024 saved members an estimated 1.5 million hours by
enabling access to care, such as selecting a PCP or understanding a benefit
• 	One in five members have closed a critical care gap through our digital channels, such as
scheduling mammograms or colonoscopies
Accessibility through advocacy and data
driven solutions that operationalize
whole health3

-- 11 of 18 --

12	12
The Value We Deliver for Care Providers
Deepen Clinical and Business Partnerships
• 	Carelon Oncology Total Cost of Care program helped to resolve adverse events for oncology
patients in lower cost settings
• 	60% of members enrolled in our Concierge Care program experienced fewer chemotherapy
side-effect related admissions
Differentiated clinical partnerships built
on shared expertise and coordinated care	1
• 	Pay for nearly two thirds of care through value-based arrangements across all lines of
business, with over 35% of payments to providers taking downside risk, up from 16% in 2021
• 	Managed nearly one million consumers through Mosaic Health across 19 states with 1,500+
providers, including 35% of lives at risk
• 	Carelon Advanced Primary Care and Millennium Physician Group achieved NPS scores of 90
Advanced clinical collaboration and
value-based care	2
• 	We partnered with a New York based health system to nearly eliminate claims denied for
incomplete or incorrect information and are scaling this solution to other care providers
• 	89% of Medicare Advantage providers are connected to HealthOS, up from only 16% in 2021
Aligned business partner through digital
tools that enhance information exchange
and reduce administrative burden3

-- 12 of 18 --

13
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and
estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements
regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could
cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports
filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent
required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include,
but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale
medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or
regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the
impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims
or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence,
to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may
negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth
opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our
ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received
from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our
ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including
medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects
of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances;
possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of
dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock
due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk
that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may
negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations;
and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

-- 13 of 18 --

14
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on the last slide of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 14 of 18 --

15	15
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share Twelve Months Ended Dec 31	Three Months Ended Dec 31
Change	2023	2024	Change	2023	2024	(In millions, except per share data)
(0.1)%	$5,987	$5,980	(51.2)%	$856	$418	Shareholders' net income
Add / (Subtract):
—	281	—	281	Business dispositions and related items 1
885	580	217	180	Amortization of other intangible assets
694	445	336	74	Net losses on financial instruments
213	224	59	66	Transaction and integration related costs2
(2)	692	(7)	12	Litigation and settlement expenses2
—	(201)	—	—	Gain on sale of business
719	268	22	—	Business optimization charges 2
(628)	(575)	(158)	(143)	Tax impact of non-GAAP adjustments
1,881	1,714	469	470	Net adjustment items
(2.2)%	$7,868	$7,694	(33.0)%	$1,325	$888	Adjusted shareholders' net income
1.8%	$25.22	$25.68	(50.1)%	$3.63	$1.81	Shareholders’ earnings per diluted share
Add / (Subtract):
—	1.21	—	1.22	Business dispositions and related items 1
3.73	2.49	0.92	0.78	Amortization of other intangible assets
2.92	1.91	1.42	0.32	Net losses on financial instruments
0.90	0.96	0.25	0.29	Transaction and integration related costs2
(0.01)	2.97	(0.03)	0.05	Litigation and settlement expenses2
—	(0.86)	—	—	Gain on sale of business
3.03	1.15	0.09	—	Business optimization charges 2
(2.65)	(2.47)	(0.67)	(0.62)	Tax impact of non-GAAP adjustments
7.92	7.36	1.99	2.03	Net adjustment items
(0.3)%	$33.14	$33.04	(31.7)%	$5.62	$3.84	Adjusted shareholders’ earnings per diluted share
Twelve Months Ended Dec 31	Three Months Ended Dec 31
Change	2023	2024	Change	2023	2024	(In millions)
2.4%	$7,715	$7,904	(39.5)%	$1,001	$606	Income before income tax expense
(1,825)	(2,051)	(529)	(527)	Net investment income
—	(201)	—	—	Gain on sale of business
694	445	336	74	Net losses on financial instruments
1,030	1,185	259	340	Interest expense
885	580	217	180	Amortization of other intangible assets
(7.5)%	$8,499	$7,862	(47.6)%	$1,284	$673	Reportable segments operating gain
1. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
2. 	Adjustment item resides in the Corporate & Other reportable segment.
3. 	Totals may not foot due to rounding.

-- 15 of 18 --

16	16
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2025 Outlook
Twelve Months Ended Dec 31	Three Months Ended Dec 31
Change	2023	2024	Change	2023	2024	(In millions)
(0.3)%	$20,087	$20,025	(3.9)%	$4,999	$4,804	Operating expense
Add / (Subtract):
—	(281)	—	(281)	Business dispositions and related items 1
(213)	(224)	(59)	(66)	Transaction and integration related costs2
2	(692)	7	(12)	Litigation and settlement expenses2
(719)	(268)	(22)	—	Business optimization charges 2
(930)	(1,465)	(74)	(359)	Net adjustment items
(3.1)%	$19,157	$18,560	(9.7)%	$4,925	$4,445	Adjusted operating expense
2.9%	$170,209	$175,204	6.0%	$42,454	$44,989	Operating revenue
(40) bp	11.8%	11.4%	(110) bp	11.8%	10.7%	Operating expense ratio
(70) bp	11.3%	10.6%	(170) bp	11.6%	9.9%	Adjusted operating expense ratio
Twelve Months Ended Dec 31	Three Months Ended Dec 31
Change	2023	2024	Change	2023	2024	(In millions)
(7.5)%	$8,499	$7,862	(47.6)%	$1,284	$673	Reportable segments operating gain
Add / (Subtract):
—	281	—	281	Business dispositions and related items 1
213	224	59	66	Transaction and integration related costs2
(2)	692	(7)	12	Litigation and settlement expenses2
719	268	22	—	Business optimization charges 2
930	1,465	74	359	Net adjustment Items
(1.1)%	$9,429	$9,327	(24.0)%	$1,358	$1,032	Reportable segments adjusted operating gain
Full Year 2025
Outlook
$30.40 to $31.10	Shareholders’ earnings per diluted share
Add / (Subtract):
$2.57	Amortization of other intangibles 3
$1.12	Net losses on financial instruments3
$1.11	Transaction and integration related costs2, 3
$0.04	Litigation and settlement expenses2, 3
Approximately ($1.09)	Tax impact of non-GAAP adjustments3
$3.75	Net adjustment items
$34.15 to $34.85	Adjusted shareholders’ earnings per diluted share
1. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
2. 	Adjustment item resides in the Corporate & Other reportable segment.
3. 	Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.

-- 16 of 18 --

17	17
Elevance Health
Reportable Segment Highlight Details
Twelve Months Ended Dec 31	Three Months Ended Dec 31
Change	2023	2024	Change	2023	2024	(In millions, Unaudited)
Operating Revenue
1.1%	$148,571	$150,275	2.8%	$36,547	$37,580	Health Benefits
6.3%	33,835	35,961	13.0%	8,827	9,977	CarelonRx
27.0%	14,147	17,961	33.4%	3,574	4,769	Carelon Services
(35.5)%	479	309	NM 5	181	(14)	Corporate & Other
9.2%	(26,823)	(29,302)	9.7%	(6,675)	(7,323)	Eliminations
2.9%	$170,209	$175,204	6.0%	$42,454	$44,989	Total Operating Revenue1
Operating Gain (Loss)
(9.4)%	$6,888	$6,243	(73.0)%	$767	$207	Health Benefits 2
10.0%	1,975	2,172	8.8%	490	533	CarelonRx
5.4%	680	717	(65.7)%	102	35	Carelon Services2
NM 5	(1,044)	(1,270)	NM 5	(75)	(102)	Corporate & Other 2,3
(7.5)%	$8,499	$7,862	(47.6)%	$1,284	$673	Total Operating Gain1,4
Operating Margin
(40) bp	4.6%	4.2%	(150) bp	2.1%	0.6%	Health Benefits
20 bp	5.8%	6.0%	(30) bp	5.6%	5.3%	CarelonRx
(80) bp	4.8%	4.0%	(220) bp	2.9%	0.7%	Carelon Services
(50) bp	5.0%	4.5%	(150) bp	3.0%	1.5%	Total Operating Margin1
1. 	See “Basis of Presentation” on page 14 herein.
2. 	Operating gain for the three and twelve months ended December 31, 2024 included $281 of business dispositions and related items excluded from adjusted shareholders' net income; including $215 for the Carelon Services
segment; and $66 for the Health Benefits segment. Operating gain for the three and twelve months ended December 31, 2024 included $66 and $224, respectively, of transaction and integration related costs, all of which resides
in the Corporate & Other reportable segment. Operating gain for the three and twelve months ended December 31, 2024 included $12 and $692, respectively, of litigation and settlement expenses, all of which resides in the
Corporate & Other reportable segment. Operating gain for the twelve months ended December 31, 2024 included $268 of business optimization charges which reside in the Corporate & Other reportable segment.
3. 	Operating gain for the three and twelve months ended December 31, 2023 included; $59 and $213, respectively, of transaction and integration related costs; $22 and $719, respectively, of business optimization charges; and ($7)
and ($2), respectively, of litigation and settlement expenses.
4. 	Operating Gain for the three and twelve months ended December 31, 2024, and December 31, 2023, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on slides 15 and 16 herein.
5. 	"NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).

-- 17 of 18 --



-- 18 of 18 --